What's news?
News
- 2013-04-26
Release of 2012 Reference Document (French only) - 2013-04-24
Q1 2013 revenues - 2013-04-23
Liquidity agreement (French only) - 2013-03-18
Adocia announces its phase III development program for the treatment of diabetic foot ulcer. This program has been validated by scientific advice from the European Medicines Agency - 2013-02-19
ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 - 2013-02-06
Bio CEO & Investor Conference - 11-12 February 2013 - The Waldorf Astoria, New York, USA - 2013-01-07
Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences - 2012-10-30
Adocia announces the strong growth of its turnover - 2012-10-22
Adocia is extending its intellectual property to new formulations of monoclonal antibodies - 2012-10-01
EASD 2012 - 48th Annual Meeting of the European Association for the Study of Diabetes - 1-5 October 2012, Messe Süd, Berlin, Germany - 2012-09-12
Bio India International Conference - 12-13 September 2012, Grand Hyatt, Mumbai, India - 2012-09-07
DFSICON 2012 - 11th Annual Meeting of Diabetic Foot Society of India - 7-9 September 2012, Hyderabad, India - 2012-09-03
Financial results and business report for the first half of 2012 - 2012-09-02
WUWHS 2012 - 4th Congress of the World Union of Wound Healing Societies - 2-6 September 2012, Yokohama, Japon - 2012-06-13
Adocia announces a strengthened intellectual property on its lead project for its chronic wounds treatment - 2012-05-30
Additional contribution to Liquidity Agreement with Dexia Securities France (French only) - 2012-04-26
ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 - 2012-04-23
ADOCIA reports positive phase II clinical results - 2012-04-02
2011 annual financial results - 2011: a key milestone in ADOCIA's development - 2012-03-15
ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial... - 2012-03-15
Liquidity agreement with Dexia Securities France (French only) - 2012-02-29
ADOCIA reports strong growth in operating income in 2011 - 2012-02-28
ADOCIA reports positive phase IIa clinical results on its fast-acting human insulin, HinsBet® - 2012-02-14
ADOCIA carries out, with much success, the first IPO of the year... - 2012-01-26
ADOCIA launches its IPO on the NYSE Euronext regulated market in Paris - 2012-01-18
ADOCIA announces the registration of its Document de base (French only) - 2011-06-24
ADOCIA launches Phase IIa clinical study on type 1 diabetic patients with its fast-acting human insulin, HinsBet® - 2011-06-15
ADOCIA announces the communication of its clinical results at three major conferences - 2011-03-15
ADOCIA reports positive phase I clinical results on HinsBet®, a fast-acting human insulin - 2010-01-05
Adocia announces today the closing of its second financing round of 14 M. - 2008-01-21
ADOCIA has raised 12 M in order to finance its development of innovative pharmaceutical products...
Contact
115 avenue Lacassagne
69003 Lyon - France
Tel: +33 (0)4 72 610 610
Fax: +33 (0)4 72 36 39 67
Home Page | ADOCIA | BioChaperone® | Products | Partnering | Investors | News | Careers
copyright ADOCIA©2011 - Terms of use - Contact


